Enzymes in addition to CYP3A4 and 3A5 mediate N-demethylation of dextromethorphan in human liver microsomes

Biopharmaceutics and Drug Disposition

Volumn 20, Issue 7, 1999, Pages 341-346

  Wang, Yi ^a   Unadkat, Jashvant D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

3 methoxymorphinan; CYP2B6; CYP3A4 5; Dextromethorphan; Dextromethorphan N demethylation; Human liver microsomes

Indexed keywords

3 METHOXYMORPHINAN; CYTOCHROME P450 3A4; DEXTROMETHORPHAN; DEXTRORPHAN; DIETHYLDITHIOCARBAMIC ACID; DRUG METABOLITE; ERYTHROMYCIN; FURAFYLLINE; INDINAVIR; KETOCONAZOLE; MEPHENYTOIN; METHOXSALEN; MIDAZOLAM; NIFEDIPINE; PACLITAXEL; QUINIDINE; SULFAPHENAZOLE; TESTOSTERONE; TROLEANDOMYCIN; UNCLASSIFIED DRUG;

ARTICLE; BIOTRANSFORMATION; DEMETHYLATION; DRUG METABOLISM; ENZYME ANALYSIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; LIVER MICROSOME; LIVER MICROSOME METABOLISM; MICHAELIS MENTEN KINETICS;

ANTIBODIES, BLOCKING; ANTITUSSIVE AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DEALKYLATION; DEXTROMETHORPHAN; DEXTRORPHAN; ENZYME INHIBITORS; HUMANS; ISOENZYMES; KINETICS; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES;

EID: 0033507633     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199910)20:7<341::AID-BDD195>3.0.CO;2-F     Document Type: Article

References (28)

1. Hickman D, Wang J, Wang Y, Unadkat J. Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. Drug Metab Dispos 1998; 26: 207-215.
2. Pan LP, De Vriendt C, Belpaire FM. In vitro characterization of the cytochrome P450 isoenzymes involved in the back oxidation and N-dealkylation of reduced haloperidol. Pharmacogenetics 1998; 8(5): 383-389.
3. Renwick AB, Mistry H, Ball SE, Walters DG, Kao J, Lake BG. Metabolism of Zaleplon by human hepatic microsomal cytochrome P450 isoforms. Xenobiotica 1998; 28(4): 337-348.
4. Pan LP, Wijnant P, De Vriendt C, Rosseel MT, Belpaire FM. Characterization of the cytochrome P450 isoenzymes involved in the in vitro N-dealkylation of haloperidol. Br J Clin Pharmacol 1997; 44(6): 557-564.
5. Gorski JC, Jones DR, Wrighton SA, Hall SD. Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 1994; 48(1): 173-182.
6. Schmider J, Greenblatt DJ, Fogelman SM, von Moltke LL, Shader RI. Metabolism of dextromethorphan in vitro: involvement of cytochromes P450 2D6 and 3A3/4, with a possible role of 2E1. Biopharm Drug Dispos 1997; 18(3): 227-240.
7. von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Venkatakrishnan K, Schmider J, Harmatz JS, Shader RI. Multiple human cytochromes contribute to biotransformation of dextromethorphan in vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A. J Pharm Pharmacol 1998; 50(9): 997-1004.
8. Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 1997; 44(2): 190-194.
9. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol regent. J Biol Chem 1951; 193: 265-275.
10. Lasker JM, Wester MR, Aramsombatdee E, Raucy JL. Characterization of CYP2C 19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. Arch Biochem Biophys 1998; 353(1): 16-28.
11. Miners JO, Smith KJ, Robson RA, McManus ME, Veronese ME, Birkett DJ. Tolbutamide hydroxylation by human liver microsomes. Kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Biochem Pharmacol 1988; 37(6): 1137-1144.
12. Veronese ME, Doecke CJ, Mackenzie PI, McManus ME, Miners JO, Rees DL, Gasser R, Meyer UA, Birkett DJ. Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochem J 1993; 289(2): 533-538.
13. Yang TJ, Krausz KW, Shou M, Yang SK, Buters JT, Gonzalez FJ, Gelboin HV. Inhibitory monoclonal antibody to human cytochrome P450 2B6. Biochem Pharmacol 1998; 55(10): 1633-1640.
14. Wang Y, Unadkat JD. Differential inhibitory capacities of indinavir (IND) and ritonavir (RIT) towards cytochrome P450 (CYP) enzymes 3A4 and 3A5. Pharm Sci 1998; Suppl. 1: S41.
15. Chang TK, Gonzalez FJ, Waxman DJ. Evaluation of triacetyl-oleandomycin, alpha-aphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch Biochem Biophys 1994; 311(2): 437-442.
16. Ekins S, Bravi G, Binkley S, Gillespie JS, Ring BJ, Wikel JH, Wrighton SA. Three- and four-dimensional quantitative structure activity relationship analyses of cytochrome P-450 3A4 inhibitors. J Pharmacol Exp Ther 1999; 290(1): 429-438.
17. Ono S, Hatanaka T, Hotta H, Satoh T, Gonzalez FJ, Tsutsui M. Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica 1996; 26(7): 681-693.
18. von Moltke LL, Greenblatt DJ, Schmider J, Duan SX, Wright CE, Harmatz JS, Shader RI. Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J Clin Pharmacol 1996; 36(9): 783-791.
19. Wang RW, Newton DJ, Scheri TD, Lu AY. Human cytochrome P450 3A4-catalyzed testosterone 6 beta-hydroxylation and erythromycin N-demethylation. Competition during catalysis. Drug Metab Dispos 1997; 25(4): 502-507.
20. Kunze KL, Trager WF. Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem Res Toxicol 1993; 6(5): 649-656.
21. Maenpaa J, Sigusch H, Raunio H, Syogelma T, Vuorela P, Vuorela H, Pelkonen O. Differential inhibition of coumarin 7-hydroxylase activity in mouse and human liver microsomes. Biochem Pharmacol 1993; 45(5): 1035-1042.
22. Cresteil T, Monsarrat B, Alvinerie P, Treluyer JM, Vieira I, Wright M. Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res 1994; 54(2): 386-392.
23. Gentile DM, Verhoeven CH, Shimada T, Back DJ. The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel. J Pharmacol Exp Ther 1998; 287(3): 975-982.
24. Ching MS, Blake CL, Ghabrial H, Ellis SW, Lennard MS, Tucker GT, Smallwood RA. Potent inhibition of yeast-expressed CYP2D6 by dihydroquinidine, quinidine, and its metabolites. Biochem Pharmacol 1995; 50(6): 833-837.
25. Kumar GN, Walle UK, Walle T. Cytochrome P450 3A-mediated human liver microsomal taxol 6 alpha-hydroxylation. J Pharmacol Exp Ther 1994; 268(3): 1160-1165.
26. Ekins S, VandenBranden M, Ring BJ, Wrighton SA. Examination of purported probes of human CYP2B6. Pharmacogenetics 1997; 7(3): 165-179.
27. Gentest Corporation 1998-1999. Catalog. Woburn, MA: Gentest, 1998; 24.
28. Guo Z, Raeissi S, White RB, Stevens JC. Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes. Drug Metab Dispos 1997; 25(3): 390-393.